ReviewDiscover oncology2025
Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Prostate cancer (PCa) is the most prevalent and leading cause of cancer-related deaths among men in most countries around the world, with sub-Saharan Africa being among the most severely affected regions. Indeed, PCa is more common and lethal in indigenous African men, African Americans, and Afro-Caribbean men as compared to their age-matched white counterparts. While the fundamental aetiology of PCa and the role of androgen signalling are well understood, the basis of this racial disparity in PCa incidence and progression remains poorly understood. In this review we revisit the potential association of human papilloma virus (HPV) and PCa. While several studies support an association between HPV and PCa progression and aggressiveness, the importance of HPV in PCa is not without controversy. Here we evaluate studies that both support and challenge a mechanistic role for HPV in PCa and discuss limitations of these studies. We offer suggestions for future studies to address the contribution of HPV to the racial disparity in PCa incidence and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.